

Orthovisc®

Hyaluronic Acid Multi-Injection

Product Brochure



**Less pain &
improved mobility**
after just
3 injections¹

.....
**Over
20 million
injections**
performed worldwide²

**Effective OA pain relief whilst reducing
the use of prescription pain medication**

The multi-injection viscosupplement provides up to six months of joint pain relief whilst reducing the use of prescription pain medications such as steroids, NSAIDs, and opioids.³

Orthovisc®

Hyaluronic Acid Multi-Injection

Orthovisc is an ultra-pure, high molecular weight injectable hyaluronic acid (HA) viscosupplement used to treat the symptoms of osteoarthritis.⁴

Less pain and improved mobility after just 3 injections


- Pain relief within 1 week of injection¹
- Pain relief for up to 6 months¹
- Reduced risk of reactions¹
- May delay total joint replacement surgery for an average of 3.6 years⁵

When injected directly into the joint space, Orthovisc lubricates, cushions, and protects, bringing pain relief that lasts up to 6 months.



Clinical evidence

A study of the effectiveness of sodium hyaluronate in the treatment of knee osteoarthritis found that after just three intra-articular injections of Orthovisc spaced one week apart, patients experienced a significant reduction in joint pain and improved mobility over a period of 27 weeks.¹



Reduced use of prescription painkillers and steroid injections

A retrospective study of nearly **30,000** patients demonstrates that Orthovisc offers effective pain alleviation among knee OA patients whilst reducing the use of prescription pain medications such as steroids, NSAIDs, and opioids.³

6-months post-injection results, statistically significant:

- Reduction in the use of NSAIDs and steroids
- Reduction in the proportion of patients filling prescriptions
- Reduction in the number of patients getting opioid prescriptions




Average number of steroid injection prescriptions were reduced by

60%
p < .001

Optimal high molecular weight HA

Results in greater pain reduction and longer duration of effect than low molecular weight or excessively high molecular weight HA.⁶




Synoviocytes

MW \leq 500,000

Low Binding Affinity

Limited stimulation of biosynthesis of HA




Synoviocytes

500,000 < MW < 4,000,000

Optimal Binding Affinity

Stimulation of biosynthesis of HA⁷



Synoviocytes

MW \geq 4,000,000

Steric Hindrance

Limited stimulation of biosynthesis of HA

1,000,000 Da < 2,900,000 Da

ORTHOVISC

Orthovisc®

Indications

Orthovisc is indicated as a viscoelastic supplement or a replacement for synovial fluid in human joints. Orthovisc is well suited to provide relief for the pain of osteoarthritis. The actions of Orthovisc are lubrication and mechanical support.⁸

Directions for use⁸

The required amount of Orthovisc is slowly infused through a sterile, disposable, ISO/ANSI-conforming, non-rigid hubbed hypodermic needle of suitable gauge into the selected joint space.

Common needle gauges for injections into the knee are 18-21 gauge. The final needle selection for any procedure is determined by the physician.

The volume will vary depending upon the size of the joint space, not to exceed 2 mL for the knee and other large joints, or 1 mL for small joints.

It is the physician's responsibility to determine the appropriate volume and ensure that the joint is not overfilled.

The recommended treatment regimen is three injections spaced one week apart for each treatment course. Not to exceed one treatment course for any individual joint in any six-month period. Any joint effusion present should be removed before injecting Orthovisc.

In the European Economic Area and other parts of the world, Orthovisc is indicated as a viscoelastic supplement or a replacement for synovial fluid in human joints.

In the United States and Canada, Orthovisc is approved solely for use in the knee.

Please refer to your regional IFU.

1 Brandt KD, Block JA, Michalski JP, et al. Efficacy and safety of intra-articular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. Clin Orthop Relat Res 2001;(385):130-43. **2** Anika Data on File. **3** Abhishek S. Chitnis, Katherine Etter, Chantal E. Holy, F. Scott Gray, Fernando J. Manalac, Brad Bisson & Samir K. Bhattacharyya (2019): Real-world impact of the high concentration non-avian high molecular weight hyaluronan on pain medication use among osteoarthritis patients. Curr Med Res Opin 2019. DOI: 10.1080/03007995.2019.1596670. **4** Peyron J. Intra-articular Hyaluronan Injections in the Treatment of Osteoarthritis: State-of-the-Art Review. J Rheumatol 1993;20(39):10-15. **5** Altman R, Lim S, Steen RG. Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. health claims database. PLoS ONE 2015; 10(12). e0145776. doi:10.1371/journal.pone.0145776 **6** Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Discord. 2015;16(321). **7** Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987;7(3):113-122. **8** Orthovisc IFU.


Anika Therapeutics, Inc.

32 Wiggins Ave., Bedford, MA 01730 USA
customerservice@anika.com

www.anika.com | Anika. Restore Active Living.® | Stay Active.®

The information contained in this brochure applies exclusively to territories outside of North America. Anika, Orthovisc, Stay Active, and Restore Active Living are trademarks and/or registered trademarks of Anika Therapeutics, Inc. and its affiliates in certain jurisdictions. WOMAC is a registered trademark of Nicholas Bellamy. ©2024 Anika Therapeutics, Inc. All rights reserved.

AML-900-682 REV 01



ANIKA
OA Pain Management